The World’s Leading Technology Provider for the Biopharma Market
Sartorius Stedim Cellca starts construction of a new 30-million-euro Cell Culture Technology Center in Ulm, Germany. The new laboratory and office complex will approximately double the company’s space and is scheduled to be completed by the end of 2019.
Sartorius Stedim Biotech enters a new field by acquiring Umetrics, a highly specialized, leading global provider of data analytics software for modeling and optimizing development and manufacturing processes.
Sartorius Stedim Biotech acquires kSep Systems that specializes in preparative centrifugation for recombinant proteins, vaccines and cell therapy products.
The company opens a new bioanalytical and biosafety testing facility in Boston, Massachusetts, USA.
Scottish-based BioOutsource Ltd. and German-based Cellca are acquired. BioOutsource provides bioanalytical testing services, and Cellca is a specialist in the development of cell lines and processes.
Sartorius Stedim Biotech purchases a majority stake in the U.S. startup AllPure Technologies LLC, which is a complementary fit to its single-use product portfolio for the biopharmaceutical industry.
The British company TAP Biosystems is acquired to bring in fermentation capabilities.
Sartorius Stedim Biotech takes over cell culture media business from Lonza, a life science company.
Sartorius Stedim Biotech acquires Swiss-based Wave Biotech AG, a leading provider of single-use bioreactors.
Sartorius AG merges its biotechnology division with Stedim S.A. Sartorius Stedim Biotech (SSB) resulting from this merger is now one of the world's leading technology providers for the biopharmaceutical industry. The new company is listed on the Paris stock exchange.
Sartorius BBI Systems GmbH, a leading manufacturer of fermenters, bioreactors and cell culture systems, is renamed to Sartorius Stedim Systems GmbH and becomes a subsidiary of Sartorius Stedim Biotech.
Stedim acquires Integrated Biosystems Inc. in Napa, California, USA, and IDC in Lourdes, France.
Stedim opens new production facilities in Concord, California, USA, and in M'Hamdia, Tunisia.
Stedim S.A. goes public in Paris, France.
Stedim conquers the market for biopharmaceutical applications with its sterile single-use bags that replace conventional steel or glass containers. The single-use concept constitutes a technological revolution for the pharmaceutical industry.
The French biotech company Stedim is founded by Bernard Lemaître and Bernard Vallot. Stedim S.A. creates the first complete system to fill and administer intravenous parenteral nutrition solutions to patients. Ethylene-vinyl acetate (EVA) bags are the central products of this system.